On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation and global licensing agreement with MediLink Therapeutics. The partnership aims to utilize MediLink’s TMALIN® antibody-drug conjugate (ADC) platform to develop a novel LRRC15 ADC drug, ZL-6201, targeting solid tumors. The antibody for this product was discovered internally by Zai Lab.
Partnership Details
Through this collaboration, Zai Lab further expands its global oncology pipeline. The companies aim to develop another potential first-in-class ADC targeting multiple solid tumors, addressing significant unmet medical needs. Preclinical studies of ZL-6201 have shown encouraging data, and an Investigational New Drug (IND) application is expected to be submitted in 2025.-Fineline Info & Tech
